Spanner In Works For UK Gvn’t’s Brexit Plans; Industry Looks To Ongoing Talks with Ministers
Executive Summary
Parliament may get to vote on the terms of the UK’s departure from the EU if an important legal decision handed down today is upheld. Industry has its eye on ongoing talks with the government.
You may also be interested in...
UK MPs On Brexit: EMA And MHRA Are ‘Completely Intermingled’
Perhaps appealing to the wider European audience, UK legislators debating Brexit’s impact warn of damage to EU and as well as UK regulatory systems.
‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System
The way in which pharmaceuticals might be regulated in the UK after the country leaves the EU is a big unknown. As MPs get to have their say on the matter, the Pink Sheet tries to gauge government thinking.
UK Pharma Chiefs To Helm Brexit Steering Committee
Sir Andrew Witty and Pascal Soriot, CEOs of GlaxoSmithKline and AstraZeneca, respectively, are to co-chair a new steering group along with George Freeman, the UK's life sciences minister. The group will address the challenges posed to the sector by the UK's decision to withdraw from the EU.